News & Developments

News & Developments

Recent HLS Therapeutics news, press releases and media articles relevant to CNS therapies.

In August 2015, HLS completed the acquisition of the North American Canadian and US rights to CLOZARIL®. The financing for this and future acquisitions was completed with the participation of leading world-class healthcare investors. The acquisition was financed using part of the proceeds of a brokered equity private placement and a syndicated loan. GMP Securities L.P. acted as lead agent and advisor, with Bloom Burton & Co. Limited and Barclays also acting as agents and advisors. Willow Tree Capital Group acted as the strategic advisor to HLS for the transaction.

The company was very pleased to see the concrete interest from investors for the brand as a foundational product for HLS to build on. 

In September 2017, HLS Licensed the rights to register, commercialize and distribute Vascepa® in Canada.

Brand names you know. Safe and effective results you trust.